Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Elizabeth D Routh"'
Autor:
Jeran K Stratford, David J Bentrem, Judy M Anderson, Cheng Fan, Keith A Volmar, J S Marron, Elizabeth D Routh, Laura S Caskey, Jonathan C Samuel, Channing J Der, Leigh B Thorne, Benjamin F Calvo, Hong Jin Kim, Mark S Talamonti, Christine A Iacobuzio-Donahue, Michael A Hollingsworth, Charles M Perou, Jen Jen Yeh
Publikováno v:
PLoS Medicine, Vol 7, Iss 7, p e1000307 (2010)
Pancreatic ductal adenocarcinoma (PDAC) remains a lethal disease. For patients with localized PDAC, surgery is the best option, but with a median survival of less than 2 years and a difficult and prolonged postoperative course for most, there is an u
Externí odkaz:
https://doaj.org/article/8637234746224f3e9ffbe1636aaf9a1d
Supplementary Figures 1-3 from Activation and Involvement of Ral GTPases in Colorectal Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8dd487690145a46fb55ac76870fb1d05
https://doi.org/10.1158/0008-5472.22387439.v1
https://doi.org/10.1158/0008-5472.22387439.v1
Autor:
Jen Jen Yeh, Janie Peacock, Temitope O. Keku, Robert S. Sandler, Channing J. Der, Tara C. Rubinas, Xiang Jun Shen, Hong Jin Kim, Timothy D. Martin, Elizabeth D. Routh
Publikováno v:
Molecular Cancer Therapeutics. 8:834-843
Phase II clinical trials of mitogen-activated protein/extracellular signal-regulated kinase (ERK) kinase (MEK) inhibitors are ongoing and ERK1/2 activation is frequently used as a biomarker. In light of the mutational activation of BRAF and KRAS in c
Publikováno v:
Cancer research. 71(1)
Current approaches to block KRAS oncogene function focus on inhibition of K-Ras downstream effector signaling. We evaluated the antitumor activity of selumetinib (AZD6244, ARRY-142886), a potent and selective MEK1/2 inhibitor, on a panel of colorecta
Publikováno v:
Journal of Surgical Research. 144:379